Although the clinical sample size was limited, the preliminary results demonstrated that the CD19/CD22 BS Loop CAR-T cells exhibited promising efficacy and safety in treating patients with r/r DLBCL, particularly showing significant advantages in CD22 targeting. Here, CD19 is linked to diffuse large B-cell lymphoma.